Ensysce Biosciences Inc banner

Intrinsic Value

ENSC doesn't have a meaningful market cap.

The intrinsic value of Ensysce Biosciences Inc (ENSC) under the Base Case is 1.9752 USD per share. Compared with the current market price of 0.4095 USD, the stock appears Undervalued by 79% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

ENSC Intrinsic Value
$1.9752
Undervaluation 79%
Intrinsic Value
Price $0.4095
Alert me when ENSC is below its intrinsic value
Today $1.5801 · Already reached, the price is 74.1% below it

ENSC is cheaper than usual. It was this cheap or cheaper on just 14% of days in the past 5 years.

Alternatives to ENSC

Fundamental Analysis

What Ensysce Biosciences Does

Biotechnology Health Care

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 8 full-time employees. The company went IPO on 2017-12-01. The firm develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose.

Headquarters
United States of America US
Employees
8
IPO date
Dec 1, 2017
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Ownership

Ensysce Biosciences insiders are buying within their usual range

Insider trading · Last trade on Aug 7, 2026

Sold $0 Nobody sold
Bought $444.2k 1 insider
Trades by date
Open insider trading

Continue ENSC Research

Decided on Ensysce Biosciences? Get an email when ENSC reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one ENSC stock?

The intrinsic value for Ensysce Biosciences Inc (ENSC) under the Base Case is 1.9752 USD.

Is ENSC stock undervalued or overvalued?

Compared with the current market price of 0.4095 USD, the stock appears Undervalued by 79% .

How reliable are our estimates? See how past valuations played out
Back to Top